BIOMODICS APS

Their core work

Biomodics is a Danish SME specializing in advanced biomaterial coatings and surface modification technologies for medical devices. Their core work involves developing polymer-based coatings that can be loaded with active substances — such as antibiotics or nanoparticles — to make implantable devices safer and more functional. They contribute materials science expertise to EU consortia tackling infection control in catheters, cell-based regenerative medicine, and implantable neural interfaces. Their technology sits at the intersection of polymer chemistry and medical device engineering, serving as a supplier of functional biomaterial solutions to clinical and academic partners.

What they specialise in

How they've shifted over time

Biomodics began with a clear focus on infection-fighting biomaterials — antimicrobial catheter coatings, nanoparticle-loaded hybrid materials, and bacterial detection for urinary tract infections (2015-2016). By 2017, their focus shifted toward more complex implantable systems, contributing materials expertise to neural interfaces, optogenetics devices, and ultrasonically-powered implants for neurological conditions. This trajectory shows a company moving from surface-level device coatings toward deeper integration into active, electronically-functional implantable systems.

Biomodics is moving from passive antimicrobial coatings toward functional biomaterials for active implantable devices, particularly in the neurotechnology space.

How they like to work

Biomodics predominantly joins consortia as a specialist partner (3 of 4 projects), contributing their biomaterials expertise to larger teams. They coordinated one small Phase 1 SME Instrument project (Bacticon1), suggesting they can lead focused feasibility studies but prefer the specialist contributor role in larger research initiatives. With 26 unique partners across 15 countries from just 4 projects, they integrate well into diverse international consortia rather than working within a narrow circle.

Despite only four projects, Biomodics has built a remarkably wide network of 26 partners across 15 countries, indicating participation in large, geographically diverse consortia. Their network spans across Europe with no single dominant geographic cluster.

What sets them apart

Biomodics occupies a niche that few SMEs fill: they are a dedicated biomaterial coating company that can serve as an industry partner in academic-heavy medical device consortia. Their ability to bridge polymer chemistry, drug delivery, and device engineering makes them a practical translational partner — they turn lab-scale surface science into manufacturable device components. For consortium builders, they offer genuine industrial biomaterials capability without the overhead of engaging a large medtech corporation.

Highlights from their portfolio

• STARDUST
  Their largest project (EUR 485,736) combining optogenetics, ultrasonics, and implantable devices for Parkinson's — a significant leap from their coating origins into neurotechnology.
• Bacticon1
  Their only coordinated project, an SME Instrument Phase 1 feasibility study on urinary tract infection detection — shows entrepreneurial initiative in infection control.